This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Yusuke Shuchi - Innovator in Antibody-Drug Conjugates
Introduction
Yusuke Shuchi is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions for cancer treatment. His work focuses on creating targeted therapies that can improve patient outcomes.
Latest Patents
Yusuke Shuchi holds a patent for an Anti-CD37 antibody-drug conjugate. This invention aims to provide an antibody that specifically binds to CD37-positive tumor cells, such as those found in malignant B-cell lymphoma. The patent encompasses an antibody-drug conjugate that includes the antibody, a pharmaceutical composition with therapeutic effects on tumors, and methods for treating tumors using this composition. The invention also details the production methods for both the antibody and the antibody-drug conjugate.
Career Highlights
Yusuke Shuchi is associated with Daiichi Sankyo Company, Limited, where he has been instrumental in advancing research and development in oncology. His innovative approach to antibody-drug conjugates has positioned him as a key figure in the fight against cancer.
Collaborations
Yusuke has collaborated with notable colleagues, including Riki Goto and Tomoko Terauchi. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Yusuke Shuchi's contributions to the field of antibody-drug conjugates represent a significant advancement in cancer therapy. His innovative work continues to pave the way for new treatment options that can improve the lives of patients battling cancer.